Axsome Therapeutics Inc
19X
Company Profile
Business description
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Contact
One World Trade Center
29th Floor
New YorkNY10007
USAT: +1 212 332-3241
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
925
Stocks News & Analysis
stocks
AI stocks stumble amid growing safety fears
Warnings from Anthropic, OpenAI, and SpaceX are raising questions over the future of the AI buildout.
stocks
Chart of the Week: BHP’s valuation hits historic levels
BHP and peers are trading as if the copper boom is here to stay.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,910.90 | 36.40 | 0.41% |
| CAC 40 | 8,186.93 | 0.00 | 0.00% |
| DAX 40 | 25,716.71 | 178.96 | 0.70% |
| Dow JONES (US) | 51,778.04 | 316.14 | 0.61% |
| FTSE 100 | 10,816.14 | 127.67 | 1.19% |
| HKSE | 24,604.29 | 109.49 | -0.44% |
| NASDAQ | 26,418.30 | 439.87 | 1.69% |
| Nikkei 225 | 64,136.25 | 213.25 | 0.33% |
| NZX 50 Index | 13,756.59 | 133.87 | 0.98% |
| S&P 500 | 7,637.76 | 85.95 | 1.14% |
| S&P/ASX 200 | 8,732.40 | 35.90 | 0.41% |
| SSE Composite Index | 3,875.60 | 16.00 | -0.41% |